Heparins designed to specifically inhibit platelet interactions with von Willebrand factor

Circulation

Volumn 93, Issue 5, 1996, Pages 992-999

  Sobel, Michael ^a,b,c   Bird, Karyn E ^a,c   Tyler Cross, Ruth ^b,c   Marques, Dalila ^a,c   Toma, Naoto ^a,c   Conrad, H Edward ^d,e   Harris, Robert B ^b,c  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^e Glycomed Inc   (United States)

Author keywords

heparin; platelet aggregation inhibitors; platelets; thrombosis; von Willebrand factor

Indexed keywords

ANTITHROMBIN III; ANTITHROMBOCYTIC AGENT; ASTENOSE; FIBRINOGEN RECEPTOR; GLYCOPROTEIN IB; HEPARIN; HEPARIN DERIVATIVE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

AFFINITY CHROMATOGRAPHY; ARTERY THROMBOSIS; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; GAS CHROMATOGRAPHY; HEMATOLOGICAL PARAMETERS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOLECULAR WEIGHT; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; THROMBOSIS PREVENTION;

EID: 0029968133     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.93.5.992     Document Type: Article

References (45)

1. Ruggeri ZM, Zimmerman TS. von Willebrand factor and von Willebrand disease. Blood. 1987;70:895-904.
2. Hawiger J. Adhesive interactions of blood cells and the vascular wall. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis. Philadelphia, Pa: JB Lippincott Co; 1994:762-796.
3. Moroose R, Hoyer LW. von Willebrand factor and platelet function. Annu Rev Med. 1986;37:157-163.
4. Badimon L, Badimon JJ, Rand J, Turitto VT, Fuster V. Platelet deposition on von Willebrand factor-deficient vessels: extracorporeal perfusion studies in swine with von Willebrand's disease using native and heparinized blood. J Lab Clin Med. 1987;110: 634-647.
5. Moake JL. Insolubilized von Willebrand factor and the initial events in hemostasis. J Lab Clin Med. 1989;114:1-3.
6. Olson JD, Zaleski A, Hermann D, Rood PA. Adhesion of platelets to purified solid-phase von Willebrand factor: effects of wall shear rate, ADP, thrombin, and ristocetin. J Lab Clin Med. 1989;114:6-18.
7. Moake JL, Turner NA, Stathopoulos NA, Nolasco L, Heliums JD. Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin. Blood. 1988;71:1366-1374.
8. Alevriadou BR, Moake JL, Turner NA, Ruggeri ZM, Folie BJ, Phillips MD, Schreiber AB, Hrinda ME, McIntire LV. Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets. Blood. 1993;81:1263-1276.
9. Antman EM, for the TIMI 9A Investigators. Hirudin in acute myocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation. 1994;90:1624-1630.
10. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty: the EPIC Investigation. N Engl J Med. 1994;330:956-961.
11. Ruggeri ZM. New insights into the mechanisms of platelet adhesion and aggregation. Semin Hematol. 1994;31:229-239.
12. Ruggeri ZM. von Willebrand factor as a target for antithrombotic intervention. Circulation. 1992;86(suppl III):III-26-III-29.
13. Ikeda Y, Handa M, Kawano K, Kamata T, Murata M, Araki Y, Anbo H, Kawai Y, Watanabe K, Itagaki I, Sakai K, Ruggeri ZM. The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. J Clin Invest. 1991;87:1234-1240.
14. Yao S-K, Ober JC, Garfinkel LI, Hagay Y, Ezov N, Ferguson JJ, Anderson HV, Panel A, Gorecki M, Buja LM, Willerson JT. Blockade of platelet membrane glycoprotein Ib receptors delays intracoronary thrombogenesis, enhances thrombolysis, and delays coronary artery reocclusion in dogs. Circulation. 1994;89:2822-2828.
15. Lawrence JB, Bodenheimer SL. Thrombin inhibition is not responsible for the inhibition of platelet adherence produced by unfractionated heparin. Blood. 1991;78S:217a.
16. Girma JP, Fressinaud E, Christophe O, Rouault C, Obert B, Takahashi Y, Meyer D. Aurin tricarboxylic acid inhibits platelet adhesion to collagen by binding to the 509-695 disulphide loop of von Willebrand factor and competing with glycoprotein Ib. Thromb Haemost. 1992;68:707-713.
17. Sobel M, McNeill PM, Carlson P, Kermode JC, Adelman B, Conroy R, Marques D. Heparin inhibition of von Willebrand factor in vitro and in vivo. J Clin Invest. 1991;87:1787-1793.
18. Meyer D, Girma J-P. von Willebrand factor: structure and function. Thromb Haemost. 1993;70:99-104.
19. Sobel M, Soler DF, Kermode JC, Harris RB. Localization and characterization of a heparin binding domain peptide of human von Willebrand factor. J Biol Chem. 1992;267:8857-8862.
20. Tyler-Cross R, Sobel M, Marques D, Soler DF, Harris RB. Heparin-von Willebrand factor binding as assessed by isothermal titration calorimetry and by affinity fractionation of heparins using synthetic peptides. Arch Biochem Biophys. 1993;306:528-533.
21. Tyler-Cross R, Sobel M, Marques D, Harris RB. Heparin binding domain peptides of antithrombin III: analysis by isothermal titration calorimetry and circular dichroism spectroscopy. Protein Sci. 1994;3:620-627.
22. Soler DF, Sobel M, Harris RB. Design and synthesis of a helix heparin-binding peptide. Biochemistry. 1992;31:5010-5016.
23. Blumenkrantz N, Asboe-Hansen G. New method for quantitative determination of uronic acids. Anal Biochem. 1973;54:484-489.
24. Teien AN, Lie M. Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III. Thromb Res. 1977;10:399-410.
25. Bethell GS, Ayers JS, Hancock WS, Hearn MT. A novel method of activation of cross-linked agaroses with 1,1′-carbonyldiimidazole which gives a matrix for affinity chromatography devoid of additional charged groups. J Biol Chem. 1979;254:2572-2574.
26. Patent No. 5250519. Non-anticoagulant heparin derivatives. Assignee 226565, Glycomed Inc, California, 1993.
27. Patent No. 5280016. Non-anticoagulant heparin derivatives. Assignee 226565, Glycomed Inc, California, 1994.
28. Guyton JR, Rosenberg RD, Clowes AW, Karnovsky MJ. Inhibition of rat arterial smooth muscle cell proliferation by heparin: in vivo studies with anticoagulant and nonanticoagulant heparin. Circ Res. 1980;46:625-634.
29. Wright TC Jr, Castellot JJ Jr, Petitou M, Lormeau J-C, Choay J, Karnovsky MJ. Structural determinants of heparin's growth inhibitory activity: interdependence of oligosaccharide size and charge. J Biol Chem. 1989;264:1534-1542.
30. Casu B. Methods of structural analysis. In: Lane DA, Lindahl U, eds. Heparin, Chemical and Biological Properties: Clinical Applications. Boca Raton, Fla: CRC Press; 1989:25-49.
31. Baruch D, Ajzenberg N, Denis C, Legendre P, Lormeau J-C, Meyer D. Binding of heparin fractions to von Willebrand factor: effect of molecular mass and affinity for antithrombin III. Thromb Haemost. 1994;71:141-146.
32. Suda Y, Marques D, Kermode JC, Kusumoto S, Sobel M. Structural characterization of heparin's binding domain for human platelets. Thromb Res. 1993;69:501-508.
33. Lawrence JB, Gralnick HR. Monocolonal antibodies to the glycoproteins involved in adhesive protein binding: effects on platelets spreading and ultrastructure on human arterial subendothelium. J Lab Clin Med. 1987;109:495-503.
34. Heras M, Chesebro JH, Webster MW, Mruk JS. Grill DE, Penny WJ, Bowie EJ, Badimon L, Fuster V. Hirudin, heparin, and placebo during deep arterial injury in the pig: the in vivo role of thrombin in platelet-mediated thrombosis. Circulation. 1990;82:1476-1484.
35. Harker LA. Platelets and vascular thrombosis. N Engl J Med. 1994; 330:1006-1007.
36. 2, an anti-guinea pig platelet glycoprotein Ib monoclonal antibody. Arterioscler Thromb. 1991;11:1231-1236.
37. Roth GJ. Developing relationships: arterial platelet adhesion, glycoprotein Ib, and leucine-rich glycoproteins. Blood. 1991;77:5-19.
38. Kohmura C, Gold HK, Yasuda T, Holt R, Nedelman MA, Guerrero JL, Weisman HF, Collen D. A chimeric murine/human antibody Fab fragment directed against the platelet GPIIb/IIIa receptor enhances and sustains arterial thrombolysis with recombinant tissue-type plasminogen activator in baboons. Arterioscler Thromb. 1993;13:1837-1842.
39. Weiss HJ, Hawiger J, Ruggeri ZM, Turitto VT, Thiagarajan P, Hoffmann T. Fibrinogen-independent platelet adhesion and thrombus formation on subendothelium mediated by glycoprotein lib-Ilia complex at high shear rate. J Clin Invest. 1989;83:288-297.
40. Coller BS, Peerschke EI, Scudder LE, Sullivan CA. Studies with a murine monoclonal antibody that abolishes ristocetin-induced binding of von Willebrand factor to platelets: additional evidence in support of GPIb as a platelet receptor for von Willebrand factor. Blood. 1983;61:99-110.
41. Moake JL, Olson JD, Troll JH Jr, Weinger RS, Peterson DM, Cimo PL. Interaction of platelets, von Willebrand factor, and ristocetin during platelet agglutination. J Lab Clin Med. 1980;96:168-184.
42. Allain JP, Cooper JA, Wagner RH, Brinkhaus KM. Platelets fixed with paraformaldehyde: a new reagent assay of von Willebrand factor and platelet aggregating factor. J Lab Clin Med. 1975;25: 318-321.
43. Hardisty RM. Molecular mechanism of platelet adhesion. Adv Exp Med Biol. 1985;192:411-418.
44. Phillips MD, Moake JL, Nolasco L, Turner N. Aurin tricarboxylic acid: a novel inhibitor of the association of von Willebrand factor and platelets. Blood. 1988;72:1898-1903.
45. 2 and heparin. Arteriosclerosis. 1983;3:141-148.